Brief Reports
Copyright ©The Author(s) 2005.
World J Gastroenterol. Jul 7, 2005; 11(25): 3905-3908
Published online Jul 7, 2005. doi: 10.3748/wjg.v11.i25.3905
Table 1 Demographic and laboratory data of healthy subjects, CHC and NAFLD (mean±SD)
Reference rangeHealthy subjectsChronic hepatitis CPNAFLDP
Age (yr)44.62 ± 11.1960.83 ± 8.55< 0.0149.48 ± 14.580.082
Sex (male:female)44:8112:170.53316:170.162
AST (IU/L)10 - 3497.17 ± 52.6274.68 ± 42.09
ALT (IU/L)7 - 33114.28 ± 61.87108.52 ± 65.07
Iron (µg/dL)60 - 160146.39 ± 48.19108.73 ± 31.06
TIBC (µg/dL)250 - 410377.93 ± 41.10361.57 ± 42.73
Transferrin saturation (%)20 - 5039.01 ± 13.2030.53 ± 9.80
Ferritin (ng/mL)Male: 18 - 294225.95 ± 178.24331.20 ± 283.82
Female: 6 - 283
Increased serum iron store (%)10/29 (34.48)12/33 (36.36)
Table 2 Statistical analysis of H63D mutation between healthy subjects and CHC, and healthy subjects and NAFLD
MaleFemaleTotal
Healthy subjects:CHC1/44:1/123/81:1/174/125:2/29
P0.3860.5390.315
Healthy subjects:NAFLD1/44:0/163/81:1/174/125:1/33
P0.9990.5390.999
Table 3 Statistical analysis of increased serum iron stores be-tween male and female patients with CHC or NAFLD
CHCNAFLD
Male:female4/12:6/178/16:4/17
P0.9130.114
Table 4 Statistical analysis of HFE mutation between patients with increased serum iron store and those without in CHC or NAFLD group
Increased serum iron storeCHCNAFLD
With:without1/10:1/190/12:1/21
P0.9990.999